Skip to main content

Table 1 Clinical Data of Patients on CAR T-Cell Therapy

From: Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy

  CAR19/22 (N = 84) CAR-BCMA (N = 16) HSCT + CAR-19/22 (N = 9) Total (N = 109)
Age
 Years, median (range) 47 (15–67) 55 (34–69) 40 (25–61) 47 (15–67)
Sex
 Female 38 (45.2) 3 (18.8) 1 (11.1) 42 (38.5)
Diseases
 B-ALL 25 (29.8) 25 (22.9)
 B-cell lymphoma 59 (70.2) 9 (100.0) 68 (62.4)
 MM 16 (100.0) 16 (14.7)
Refractory or relapse
 Primary refractory 21 (25.0) 3 (18.8) 4 (44.4) 28 (25.7)
 First relapse 30 (35.7) 3 (18.8) 1 (11.1) 34 (31.2)
  ≥ Second relapse 33 (39.3) 10 (62.5) 4 (44.4) 47 (43.1)
Prior HSCT
 Autologous 15 (17.9) 7 (43.8) 0 (0.0) 22 (20.2)
 Allogeneic 3 (3.6) 0 (0.0) 0 (0.0) 3 (2.8)
CAR-T cell dose, ×106 cells/kg, median (range)
 CART19 4.0 (1–10.0) 3.3 (1.8–10.0) 4.0 (1.0–10.0)
 CART22 4.8 (1–13.5) 4.2 (1.8–10.0) 4.6 (1.0–13.5)
 CART-BCMA 9.9 (5.4–20.0) 9.9 (5.4–20.0)
Neutropenia duration
 Days, median (range) 12 (0–30) 7 (2–16) 11 (2–15) 11 (0–30)
CRS grading
 Grade 0–2 75 (89.3) 14 (87.5) 9 (100.0) 98 (89.9)
 Grade 3–5 9 (10.7) 2 (12.5) 0 (0.0) 11 (10.1)
Overall response ratea 70 (83.3) 13 (81.3) 8 (88.9) 91 (83.5)
  1. Data are presented as number of patients (percentage in each therapeutic group) unless otherwise indicated. aOverall response rate was assessed in the first month after CTI